## AMENDMENTS TO THE SPECIFICATION

**Immediately after the Title of the Invention, please add the following paragraph:**

This application is U.S. National Phase of International Application PCT/AU2004/001675, filed November 26, 2004 designating the U.S., and published in English as WO 2005/052159 on June 9, 2005, which claims priority to Australian Patent No. 2003906613, filed November 28, 2003, both of which are hereby expressly incorporated by reference in their entireties.

**On page 18 of the Specification please replace the following paragraph:**

Furthermore, the peptide fragment may be derived from the C-terminal end of the IL-10 homologue. For example, the fragment may comprise one or more amino to acids, or a combination thereof, of a unique 12 amino acid sequence VSVSVAALSAQR (SEQ ID NO: 11), and in such an example, the peptides may overlap this unique region.

**On page 18-19 of the Specification please replace the following paragraph:**

In preparing antibodies for use in the invention, a protocol such as that set out in the following may be used. The cDNA sequence of the IL-10 homologue or variant or fragment thereof is cloned into a vector, such as pcDNA3.1 *myc*-His to generate a carboxyl terminal *myc*-His tagged IL-10 homologue or expression vector. This vector is then transformed into *E. coli* and the expressed protein affinity purified. The purified IL-10 homologue protein may be used to generate rabbit polyclonal antiserum using methods known in the art, such as, a commercial production service. In addition to whole IL-10 homologue or variant or fragment thereof protein, unique synthetic peptides, such as peptides whose amino acid sequence overlaps all or part of the unique, non homologous C- terminal portion of IL-10 homologue or variant or fragment thereof as (VSVSVAALSAQR) (SEQ ID NO: 11) may be used as immunogens to generate rabbit polyclonal antiserum. The specificity of the resulting antibodies will be determined by immunoblotting against purified IL-10 homologue, human IL10 and cmvIL10 (human IL10 and cmvIL10 are available commercially). Based upon these results, monoclonal antibodies can be generated against whole or a part of the IL-10 homologue.

**On pages 33-34 of the Specification please replace Table 1 with the following Table:**

| Primer | Sequence | Pair | Unspliced | Spliced | Spliced |
|---|---|---|---|---|---|

| | | | | Intron 1 | intron 1 & 2 |
|---|---|---|---|---|---|
| JAS-53 | 5'-ACTATTCTAACCGCGGAAG-3' (SEQ ID NO: 2) | JAS-R4 | 712 | 636 | 553 |
| | | JAS-R5 | 803 | 727 | 644 |
| JAS-52 | 5'-CATAAAGGACCACCTACCTGGGA-3' (SEQ ID NO: 3) | JAS-R4 | 655 | 579 | 496 |
| | | JAS-R5 | 746 | 670 | 587 |
| JAS-F1 | 5'-TACAAAGCCGCAGTGTCGTCCAGAGGATTACG-3' (SEQ ID NO: 4) | JAS-R1 | 247 | 171 | N/A |
| | | JAS-B1 | 346 | 270 | N/A |
| | | JAS-R5 | 588 | 512 | 429 |
| JAS-P3 | 5'-CAGATTGCAAGATCTCCGCGTCACCTT-3' (SEQ ID NO: 12) | JAS-R4 | 461 | 385 | 302 |
| JAS-R1 | 5'-CAACAACCAGTCCATGACGCTGCATC-3' (SEQ ID NO: 5) | JAS-F1 | 247 | 171 | N/A |
| JAS-B1 | 5'-GTAGATGGATTCTAGCGTCGAGCGCAT-3' (SEQ ID NO: 6) | JAS-F1 | 346 | 270 | N/A |
| JAS-R4 | 5'-TCCTGAGACAGCCGACTAATCACGGAC-3' (SEQ ID NO: 7) | JAS-53 | 712 | 636 | 553 |
| | | JAS-52 | 655 | 579 | 496 |
| | | JAS-P3 | 461 | 385 | 302 |
| JAS-R5 | 5'-TCTCGAGTGCAGATACTCTTCGAGACGG-3' (SEQ ID NO: 8) | JAS-53 | 803 | 727 | 644 |
| | | JAS-52 | 746 | 620 | 587 |
| | | JAS-F1 | 588 | 512 | 429 |
| JAS-R6 | 5'-GACCACCGTACCGTCGAGCCACACGGAG-3' (SEQ ID NO: 9) | Probe | N/A | N/A | N/A |

**Please add the Abstract provided herewith as the last page of the Specification.**